Tournez votre écran pour profiter de l'ensemble
du contenu du site SAVENCIA
Tournez votre écran pour profiter de l'ensemble
du contenu du site SAVENCIA

Financial datas

2025 net sales

 

Revenue for 2025 decreased by -2.6% compared to the previous fiscal year, reaching €6,956.6 million. However, organic growth remains resilient at +1.6%. The structural effect of +0.1% is driven by the integration of Ugalait SAS on July 1, 2024. The combined impact of currency exchange and hyperinflation is unfavorable at -4.3%.

2025 net sales and variation 2025-2024

BY ACTIVITY

Cheese Products account for 57.7% of consolidated revenue. Revenue declined by -1%. At constant exchange rates and scope, revenue from Cheese Products remains stable. This performance reflects a decrease in volumes due to inflationary pressure on consumption, particularly in France and Europe, as well as price increases in an inflationary context.

 

Other Dairy Products represent 45.8% of consolidated revenue, down -4.3%, including organic growth of +3.8%. This increase is driven by strong momentum in international markets and the development of
specialty ingredients.

2025 net sales by region

Current operating profit

 

 

 

 

Current operating profit decreased by -9.4%, including a scope effect of +0.1% and a negative currency impact of -7.1%.

Group share of net income

Group share of net income decreases by -30.2%. Non-recurring expenses increased by €20.1 million, mainly driven by restructuring costs, legal disputes, and asset impairment. Financial expenses rise by €5.1 million, mainly due to the negative impact of rising interest rate. The monetary position result grows by €9.6 million, reflecting the application of IAS 29 to countries experiencing hyperinflation (Argentina). The contribution from equity-accounted companies increases by €1.6 million. Corporate income tax rises by €1.1 million. Net income attributable to noncontrolling interests decreases by €4.6 million.

Net financial indebtedness / equity

 

 

 

 

The financial debt increases by €68.8 million to €415.5 million. Equity decreases by €49.2 million compared to 2024.